Lupin Launches Generic Sugammadex Injection in the US Following FDA Approval
Lupin launches Sugammadex Injection in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The bioequivalent version of Merck's Bridion Injection is indicated for reversing neuromuscular blockade in adult and paediatric patients aged two years and older undergoing surgery.
Sugammadex Injection | 31/07/2026 | By News Bureau
Gland Pharma Receives US FDA Approval for Generic Sugammadex Injection
Gland Pharma has secured US FDA approval for its generic Sugammadex Injection and launched the product in the US, strengthening its injectable portfolio in a market valued at approximately USD 1.6 billion annually.
Sugammadex Injection | 29/07/2026 | By News Bureau | 112
Glenmark Launches Generic Sugammadex Injection in US
Glenmark has launched generic Sugammadex Injection in the US, a bioequivalent and therapeutically equivalent version of Merck's BRIDION Injection.
Sugammadex Injection | 29/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy